Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))

  1. De Miguel, R.
  2. Rial-Crestelo, D.
  3. Dominguez-Dominguez, L.
  4. Montejano, R.
  5. Esteban-Cantos, A.
  6. Aranguren-Rivas, P.
  7. Stella-Ascariz, N.
  8. Bisbal, O.
  9. Bermejo-Plaza, L.
  10. Garcia-Alvarez, M.
  11. Alejos, B.
  12. Hernando, A.
  13. Santacreu-Guerrero, M.
  14. Cadiñanos, J.
  15. Mayoral, M.
  16. Castro, J.M.
  17. Moreno, V.
  18. Martin-Carbonero, L.
  19. Delgado, R.
  20. Rubio, R.
  21. Pulido, F.
  22. Arribas, J.R.
Journal:
eBioMedicine

ISSN: 2352-3964

Year of publication: 2023

Volume: 89

Type: Erratum

DOI: 10.1016/J.EBIOM.2023.104486 GOOGLE SCHOLAR

Sustainable development goals